Curis Inc. (CRIS) had a rough trading day for Monday April 15 as shares tumbled 8.7%, or a loss of $-0.18 per share, to close at $1.89. After opening the day at $2.05, shares of Curis Inc. traded as high as $2.09 and as low as $1.83. Volume was 438,015 shares over 943 trades, against an average daily volume of n/a shares and a total float of 33.15 million.
As a result of the decline, Curis Inc. now has a market cap of $62.65 million. In the last year, shares of Curis Inc. have traded between a range of $3.33 and $0.60, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Curis Inc. is based out of Lexington, MA and has some 31 employees. Its CEO is James E. Dentzer.